



Paris, 19th of June 2020



MANIFESTO OF FRENCH PHARMACEUTICAL SYNTHESIS COMPANIES IN FAVOUR OF INNOVATIVE, PRAGMATIC AND EFFECTIVE RELOCATION ON EXISTING INSTALLATIONS

The coronavirus crisis highlights the need for an efficient, reactive and competitive industrial fabric in Europe to guarantee the security of supply of essential medicines for the health of our citizens. Securing the supply of medicines means first of all re-developing the production of active ingredients and their intermediates on our territories. To achieve this, we can already rely on an existing French industrial fabric that combines expertise and know-how and that has very high levels of quality, safety and respect for the environment. It will then have to be developed and modernized in order to meet essential needs that can no longer be met today, and thus reduce our health dependence.

Since the beginning of the coronavirus crisis, our 10,000 employees at more than 60 sites throughout France have been fully mobilized to ensure the production of the active ingredients and pharmaceutical intermediates that are essential to guarantee a safe supply of medicines to our hospitals and pharmacies. In this complex and global drug production chain, our companies, players in pharmaceutical synthesis, represent one of the essential links in the chain to guarantee the long-term safety of our country's health.

Our companies have withstood the wave of massive relocation of a large part of this value chain that has gradually led the European pharmaceutical industry to depend on Asia (India and China). Today more than ever, we are seeing the consequences of this movement on our health sovereignty. Our dependence is very high, and we are no longer in a position to remedy this in the short term. In fact, drug shortages continue to grow in France and in all European countries. In order to continue to ensure the production of active ingredients, pharmaceutical intermediates and regulated raw materials on our territory, in compliance with strict quality, safety and environmental standards, we have continued to invest in the best technologies available and to improve the flexibility and productivity of our facilities to meet an ever more demanding demand and a competition that is not always subject to the same regulatory constraints (quality, safety, environment).

In this way, our companies have acquired unrivalled know-how enabling them to provide rapid and concrete responses to tomorrow's challenges. It is around these skills and facilities that a European

pharmaceutical synthesis industry that is innovative, exemplary, of high quality and competitive must be rebuilt. A national pharmaceutical synthesis plan must be implemented as soon as possible and be based on:

- (i) securing the production of active ingredients and strategic intermediates, coordinated at the European level;
- (ii) support for investment in new processes and innovative means of production to further improve the economic and environmental performance levels of our facilities;
- (iii) revised European regulations that integrate the requirement for continuity of supply and sustainability of manufacturers;
- (iv) training and skills development for employees in this sector.

The idea that we are all defending, as essential players in the value chain, is not to relocate all needs, but to favor the most critical chains, to modernize and develop existing sites as a priority so that they are able to guarantee this security of supply and to support the rapid development of innovative, competitive and less environmentally-impacting processes.

As responsible and committed players, we are ready to take up the challenge.

List of signatories (here below) o Vincent TOURAILLE | Chairman | SICOS Biochemistry o Jacques BROM | CEO | SANOFI CHEMICALS o Laurent CARMONA | Director of Industrial Operations | SPEICHIM PROCESSING o Pierre CHARRIER | CEO | DIVERCHIM o Bernard FRAISSE | Chairman & CEO | FAREVA o Frédéric GAUCHET | CEO | MINAKEM o Pierre GIULIANO | CEO | LA MESTA CHIMIE FINE o Philippe GUERRET | CEO | M2i Life Sciences o Alexandre GRUMAN | CEO | PMC Isochem o Pierre LUZEAU | CEO | SEQENS o Jean MAZERES | CEO - Strategy & Sourcing | UNIPLEX SOLUTIONS France S. A.S. o David SIMONNET | Chairman & CEO | AXYNTIS Group o Dr. Michel SPAGNOL | Chairman & CEO | NOVASEP o Pierre VENESQUE | CEO | ORIL (SERVIER Group)

Contacts SICOS Biochimie (Syndicat de l'Industrie Chimique Organique de Synthèse et de la Biochimie) : o Vincent TOURAILLE (Président) : vincent.touraille@m2i-ls.com - 06 85 82 75 07 o Catherine LEQUIME (Délégué Général) - clequime@sicos.fr - 01 46 53 10 17